{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:43:53Z","timestamp":1753868633645,"version":"3.41.2"},"reference-count":14,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To date, almost all studies regarding chimeric antigen receptor (CAR)\u2010T cell therapy for B\u2010cell acute lymphoblastic leukemia (B\u2010ALL) were performed in refractory\/relapsed (r\/r) or minimal residual disease\u2010positive patients. CAR\u2010T therapy in remission patients has not been reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To observe the treatment outcome of CAR\u2010T cells for remission B\u2010ALL patients with poor prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Results<\/jats:title><jats:p>CAR\u2010T treatment was applied to two B\u2010ALL patients in remission status who had poor prognostic factors and refused transplantation, and one case was unable to accept standard chemotherapy owing to multiple complications. The procedure of CAR\u2010T therapy in these two remission patients was the same as that in r\/r B\u2010ALL patients. Lentiviral vectors encoding second generation CARs composed of CD3\u03b6 and 4\u20101BB were used to produce CAR\u2010T cells. Lymphodepleting agents fludarabine and cyclophosphamide were administered prior to cell infusion. Grade I cytokine release syndrome occurred after each T\u2010cell infusion and there was no neurotoxicity. CAR\u2010T treatment followed by non\u2010intensive maintenance chemotherapy and targeted drugs allowed both patients to obtain a long\u2010term event\u2010free survival of more than three and a half years without transplantation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>CAR\u2010T therapy could be used in high\u2010risk B\u2010ALL patients as a consolidation to avoid transplantation, the combination of CAR\u2010T and following maintenance therapy may be better than CAR\u2010T alone for durable remission.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.1706","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T01:34:30Z","timestamp":1661218470000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["<scp>CAR\u2010T<\/scp> therapy as a consolidation in remission <scp>B\u2010ALL<\/scp> patients with poor prognosis"],"prefix":"10.1002","volume":"5","author":[{"given":"Zhichao","family":"Yin","sequence":"first","affiliation":[{"name":"Department of Hematology Beijing Boren Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuehui","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematology Beijing Boren Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology Beijing Boren Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunrong","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Hematology Beijing Boren Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9982-7099","authenticated-orcid":false,"given":"Shuangyou","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology Beijing Boren Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0488-7"},{"key":"e_1_2_11_8_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 5.2017."},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-743252"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-726588"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26160"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000172"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0280-y"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001463"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1706","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.1706","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T11:17:49Z","timestamp":1692616669000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.1706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1002\/cnr2.1706"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.1706","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"type":"print","value":"2573-8348"},{"type":"electronic","value":"2573-8348"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"assertion":[{"value":"2021-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1706"}}